Chen et al. suggested that IGF-1R antagonism alleviates pain-related behaviors and neuroinflammation [30], Li et al. found that IGF-1R inhibitor alleviated pain behaviors [35], Forster et al. showed that IGF-1R inhibition attenuates hyperalgesia [36], and Smith et al. found that teprotumumab reduced proptosis in the Clinical Activity Score and improved quality of life in patients with thyroid-associated ophthalmopathy [39]. The gene discussed is IGF1R; the disease is Graves ophthalmopathy.